瑞巴派特辅治胃溃疡伴胃出血患者的疗效观察及不良反应分析  

Clinical observation and adverse reaction analysis of rebamipide in the treatment of gastric ulcer with gastric hemorrhage

作　　者：莫炯灵 MO Jiongling(Third Geriatrics Department , Hunan Provincial People's Hospital, Changsha, Hunan 410006, China)

机构地区：[1]湖南省人民医院老年三科

出　　处：《临床合理用药杂志》2019年第23期17-18,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察胃溃疡伴胃出血患者给予瑞巴派特辅助治疗的临床效果及安全性。方法选取医院收治的胃溃疡伴胃出血患者69例为研究对象,随机分为对照组34例和观察组35例。对照组实施常规用药治疗,观察组在常规用药基础上加用瑞巴派特进行辅助治疗,比较2组治疗后的出血缓解时间,血清IL-2、IL-6、C反应蛋白(CRP)水平;治疗优良率及不良反应发生率。结果观察组治疗后的出血缓解时间短于对照组,血清IL-2、IL-6、CRP水平优于对照组(P均<0. 01);观察组治疗优良率为94. 29%,高于对照组的73. 53%(P <0. 05);2组不良反应发生率比较差异无统计学意义(P> 0. 05)。结论胃溃疡伴胃出血患者给予瑞巴派特辅助治疗的临床效果显著,安全性高,利于患者预后。Objective To observe the clinical effect and safety of rebamipide in the treatment of gastric ulcer with gastric bleeding. Methods Sixty-nine patients with gastric ulcer and gastric hemorrhage were randomly divided into observation group (35 cases) and control group (34 cases). Patients in the control group received conventional medication, and the observation group received supplemental treatment with rebamipide on the basis of the control group. The bleeding relief time, IL-2, IL -6, serum C-reactive protein (CRP) levels, excellent rate of treatment, and incidence of adverse reactions were compared between the two groups. Results After treatment, the bleeding time of the observation group was shorter than that of the control group, and the levels of IL-2, IL-6 and serum CRP were better than those of the control group (P < 0 . 01 ). The excellent and good rate of treatment in the observation group was 94. 29%, which was higher than that in the control group (73. 53%)( P < 0 . 0 5 ). There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0. 0 5 ). Conclusion The clinical effect of using rebamipide in the treatment of gastric ulcer with gastric hemorrhage is significant, and it is safe and beneficial to the prognosis of patients.

关 键 词：瑞巴派特 胃溃疡 胃出血 有效性 不良反应 

分 类 号：R573.1[医药卫生—消化系统]